Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
Phase 2
Terminated
- Conditions
- Sarcoma
- Interventions
- Drug: RG1507
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 317
- Registration Number
- NCT00642941
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸UCLA School Of Medicine Mattel's Children's Hospital At UCLA; Division Of Hematology-Oncology, Los Angeles, California, United States
🇺🇸Pennsylvania Oncology Hema Asc, Philadelphia, Pennsylvania, United States
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
Phase 2
Terminated
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT00642603
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
Phase 3
Completed
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: PlaceboDrug: tocilizumab [RoActemra/Actemra]Drug: Non-steroidal anti-inflammatory drugs (NSAIDs)Drug: methotrexateDrug: corticosteroids
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 112
- Registration Number
- NCT00642460
A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT00642473
A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT00642304
- Locations
- 🇳🇱
Albert Schweitzer Ziekenhuis; Inwendige Geneeskunde, Dordrecht, Netherlands
🇳🇱Nij Smellinghe Ziekenhuis; Inwendige Geneeskunde, Drachten, Netherlands
🇳🇱Oosterscheldeziekenhuis, Goes, Netherlands
A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT00642668
- Locations
- 🇧🇪
ZNA Stuivenberg, Antwerpen, Belgium
🇧🇪ZNA Middelheim, Antwerpen, Belgium
🇧🇪CH EpiCURA Site Hornu, Hornu, Belgium
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT00642733
STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 188
- Registration Number
- NCT00642850
A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 127
- Registration Number
- NCT00642967
A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 235
- Registration Number
- NCT00623428
© Copyright 2025. All Rights Reserved by MedPath